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Abstract 
A series of twenty new chloropyrazine conjugated benzothiazepines (22-41) have been 
synthesized with 58%–95% yields. The compounds were characterized by using different 
spectroscopic techniques including FT-IR, 1H NMR, 13C NMR spectroscopy and mass 
spectrometry. The synthesized compounds (22-41) and their precursor chalcones (2-21) were 
evaluated for antitubercular and cytotoxic activities. Additionally, compounds 22-41 were 
also tested for antimicrobial activity. Among the chalcone series (2-21), compounds 7 and 14 
showed significant antitubercular activities (MICs 25.51 and 23.89 µM, respectively), 
whereas among benzothiazepines (22-41), compounds 27 and 34 displayed significant 
antimicrobial (MICs 38.02 µM, 19.01 µM) and antitubercular (MIC 18.10 µM) activities. 
Compounds 7 and 41 displayed cytotoxic activities with IC50 of 46.03 ± 1 and 35.10 ± 2 µM 
respectively. All the compounds were evaluated for cytotoxic activity on normal human liver 
cell lines (L02) and found to be relatively less selective towards this cell line. The most active 
compounds identified through this study could be considered as potential leads for the 
development of drugs with possible antimicrobial, antitubercular, and cytotoxic activities. 
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1. Introduction 
Heterocyclic compounds play a vital role in the design and development of drugs against 
different diseases. More than seventy percent of drugs used in therapy contain one or more 
heterocyclic rings. Out of the 24 small drug molecules approved in 2020 by Food and Drug 
Administration (FDA), USA, 22 drugs contain heterocyclic rings. Similarly, of the 10 top 
drugs prescribed in USA, six drugs contain heterocyclic rings. This scenario is due to the 
property of the heterocyclic rings to serve as useful templates to modulate physicochemical 
properties of the drug molecules including the hydrogen bond capacity, polarity, and 
lipophilicity. Presence of hetero atoms or heterocyclic nucleus within the molecules may 
further improve pharmacokinetic, pharmacodynamic, and toxicological profiles of the drug 
candidates and finally drug molecules (Gomtsyan, 2012). Some of the heterocyclic rings are 
considered as privileged because of their significant drug-like properties. Medicinal chemists 
usually club or conjugate two or more such privileged heterocycles to create biologically 
useful molecules as a part of drug discovery programs. In the recent past, the design and 
synthesis of heterocyclic hybrids have received greater attention due to their ease of synthesis 
and improved biological properties. The structures that evolve from such conjugation are 
usually rigid frameworks that can show the appended rings in a well‐defined fashion that is 
necessary for molecular recognition of the biological target. Usually, the variable nature of 
these functionalities defines the selectivity on a privileged core for a particular target.  
Pyrazine and 1,5-benzothiazepine rings are two privileged aromatic heterocycles of interest 
to organic and medicinal chemists because of their ease of synthesis and biological activities. 
Both these scaffolds are prominent in a variety of drugs used in the treatment of different 
complications. For example, pyrazine ring is found in drugs like pyrazinamide (PZA) and 
morinamide (antitubercular), favipiravir (anti-corona viral), glipizide (antidiabetic), 
amiloride and benzamil (diuretic), acipimox (antihyperlipidemic), and bortezomib (multiple 
myeloma). 1,5-benzothiazepine scaffold is present in calcium channel blockers for 
cardiovascular problems- Diltiazem and Clentiazem (Nagao et al., 1972, Chaffman and 
Brogden, 1985), atypical antipsychotic agents- Quetiapine and Clotiapine, and the 
 
antidepressant drug- Thiazesim (Kawakita et al., 1991, Geyer III et al., 1970, Hopenwasser et 




Figure 1. Representative structures of clinically used pyrazine and benzothiazepine ring containing 
drugs. 
 
Pyrazine derivatives were reported to possess excellent antitubercular (Ambrożkiewicz et al., 
2020, Bouz et al., 2020, Zitko et al., 2018, Miniyar et al., 2017, Zitko et al., 2016, 
Servusova-Vanaskova et al., 2015, Servusová et al., 2013, Zitko et al., 2013, Mangrolia and 
Osborne, 2020), anticancer (De Wang et al., 2020, Tantawy et al., 2020, Etaiw et al., Seo et 
al., 2020, Mamedova et al., 2019, Patil et al., 2019, Bhaskar et al., 2020), antimicrobial 
(Singh et al., 2020, Kucerova-Chlupacova et al., 2016, Kucerova-Chlupacova et al., 2015, 
Stepanić et al., 2019, Kucerova-Chlupacova et al., 2018), antioxidant (Cavalier et al., 2001, 
Zaki et al., 2018, Abu-Hashem and El-Shazly, 2018), analgesic and anti-inflammatory 
(Shankar et al., 2017, Aneesa et al., 2015, Bills et al., 1939, Bariwal et al., 2008), and 
anti-pellagra activities (El-Bayouki, 2011). Many authors have reviewed the synthesis, 
characterization, and applications of benzothiazepines (Deshmukh et al., 2016, Saha et al., 
2015, El-Bayouki, 2013, Sekhar, 2014, Shaik et al., 2020, Wu et al., 2017). This ring 
derivatives have shown promising anticancer (Gudisela et al., 2017, Ameta et al., 2012, Arya 
and Dandia, 2008, Ansari et al., 2008, Sharma et al., 1997, Upadhyay et al., 2012, Wang et 
al., 2020), antitubercular (Kendre et al., 2019), antibacterial and antifungal (Yan et al., 2019, 
 
Tongxiu et al., 2018, Pant et al., 2018, Mor et al., 2017, B Patel et al., 2016, Li et al., 2017, 
El-Bayouki, 2013), antiviral (Di Santo and Costi, 2005, Kishor et al., 2017, Lokesh et al., 
2017) activities. Representative structures of important pyrazine and benzothiazepine 
derivatives with potential antimycobacterial, antimicrobial, and anticancer activities are 
displayed below (Fig. 2).  
 
 
Figure 2. Structures of selected pyrazine and 1,5-benzothiazepine derivatives with potent 
antimicrobial, antitubercular and anticancer activities. 
 
In continuation for our interest in the synthesis and screening of heteroaryl chalcones (Shaik 
et al., 2020, Lokesh et al., 2019) and conjugated heterocycles (Palleapati et al., 2019, Lokesh 
et al., 2019, Yazdan et al., 2015) as well as the potential bioactivities of conjugated 
heterocyclic derivatives, we prepared and screened novel chloropyrazine conjugated 
1,5-benzothiazepine derivatives. Both pyrazine and 1,5-benzothiazepine rings exhibited 
promising antimicrobial, antitubercular and cytotoxic activities as discussed above. Hence, 
the molecules synthesized for our study were expected to possess collective effect on the 
proposed activities. We have previously described the antibacterial & antifungal activities of 
chloropyrazine chalcones (2-21) [Vegesna et al., 2017]. Herein, we reported the synthesis of 
twenty new chloropyrazine conjugated benzothiazepines (22-41) as well as the antitubercular 
and cytotoxic activities of precursor chalcones (2-21), antimicrobial, antitubercular, and 
 
cytotoxic activities of chloropyrazine conjugated 1,5-benzothiazepine derivatives (22-41). 
The general structures of the chloropyrazine chalcones and chloropyrazine conjugated 
1,5-benzothiazepines are portrayed in Fig. 3. 
 
 
Figure 3. General structures of 2-acetyl-5-chloropyrazine chalcones and chloropyrazine conjugated 
1,5-benzothiazepine derivatives 
2. Materials and methods 
2.1. General 
All solvents and reagents were obtained from S.D. Fine. Ltd. Mumbai, India and Sigma 
Aldrich Chemical Co (USA) and used without further purification. Pre-coated silica gel 60 
F254 plates were used for thin-layer chromatography (TLC) and the spots on the TLC plates 
were visualized by UV lamp (254 nm). The benzothiazepines (22-41) were purified by 
recrystallization using ethanol. Melting points were determined on Boetius melting point 
apparatus in open capillary tubes and were uncorrected. FT-IR spectra were recorded on 
Bruker Vertex 80v spectrometer using potassium bromide discs and the absorption band 
values are given in cm-1. Proton and carbon magnetic resonance (1H NMR and 13C NMR) 
were recorded on Bruker AMX 400 NMR spectrophotometer using Tetramethyl silane 
(TMS) as internal standard and the chemical shift values are given in parts per million (ppm) 
relative to TMS. Mass spectra (MS) were recorded on Agilent 6100 QQQ ESI mass 
spectrophotometer by electron spray ionization technique.  
2.2. Experimental 
2.2.1 General procedure for the synthesis of chalcones (2-21) 
To a mixture of 2-acetyl-5-chloropyrazine (0.001 M) and the appropriate aryl or heteroaryl 
aldehyde (0.001 M) was stirred in ethanol (7.5 mL) and to it aqueous solution of NaOH (40 
%, 7.5 mL) was added. The mixture was kept for 24 h and it was acidified with 1:1 mixture of 
 
hydrochloric acid and water, then it was filtered under vacuum and the product was washed 
with water (Vegesna et al., 2017). 
2.2.2 General procedure for the synthesis of chloropyrazine conjugated 
1,5-benzothiazepines (22-41) 
To a mixture of 1 mmol of chalcones (2-21) and 1.5 mmol of 2-Aminothiophenol in dry 
methanol (50 mL), a catalytic amount of piperidine was added. The mixture was refluxed for 
8 h. After cooling, the solid product separated was collected and washed with diethyl ether (2 
x 50 mL) and cold methanol (2 x 50 mL). The crude solid was recrystallized from ethanol 
(Shaik et al., 2020). 
 
 
Scheme 1. Synthesis of target compounds (2-21) and (22-41): (a) Ethanol, NaOH, room temperature 
(b) 2-Aminothiophenol, Piperidine/Ethanol, reflux 
2.2.1.1.  2,3-Dihydro-2-phenyl-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (22): FT-IR 
(KBr): 1584 (C=N), 1510 (C=C), 1395 (C-N), 663 (C-S), 879 (C-Cl), 3032 (Ar C-H); 1H 
 
NMR (400 MHz, CDCl3): 5.11 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.52 (dd, J3a,3b = 
14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.21 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 
7.19-8.22 (11H, Ar-H); 13H NMR (100 MHz, CDCl3): 50.15 (C-2), 40.24 (C-3), 164.66 
(C-4), 122.54, 126.44, 127.51, 127.81, 128.80, 133.31, 141.72, 144.46, 146.73, 150.32 and 
151.45 (Ar-C’s); MS (m/z): [M+], 351.15, [M+2], 353.15. 
2.2.1.2.  2,3-Dihydro-2-(4-chlorophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine 
(23): FT-IR (KBr): 1590 (C=N), 1505 (C=C), 1395 (C-N), 660 (C-S), 841 (C-Cl), 3021 (Ar 
C-H); 1H NMR (400 MHz, CDCl3): 5.23 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.54 
(dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.29 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, 
C3-H-3b), 7.15-8.01 (10H, Ar-H). 
2.2.1.3. 2,3-Dihydro-2-(4-fluorophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (24): 
FT-IR (KBr): 1593 (C=N), 1512 (C=C), 1397 (C-N), 665 (C-S), 922 (C-Cl), 921 (C-F), 3070 
(Ar C-H); 1H NMR (400 MHz, CDCl3): 5.31 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 
3.81 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.37 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, 
C3-H-3b), 7.76-8.85 (10H, Ar-H). 
2.2.1.4.  2,3-Dihydro-2-(4-nitrophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (25): 
FT-IR (KBr): 1591 (C=N), 1512 (C=C), 1369 (C-N), 681 (C-S), 854 (C-Cl), 3059 (Ar C-H), 
1558 (N=O, asymmetric), 1341 (N=O, symmetric); 1H NMR (400 MHz, CDCl3): 5.33 (dd, 
J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 4.01 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, 
C3-H-3a), 3.73 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 7.70-8.56 (10H, Ar-H). 
2.2.1.5. 2,3-Dihydro-2-(2,4-fluorophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine 
(26): FT-IR (KBr): 1602 (C=N), 1518 (C=C), 1403 (C-N), 691 (C-S), 856 (C-Cl), 919 (C-F), 
3060 (Ar C-H); 1H NMR (400 MHz, CDCl3): 5.45 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, 
C2-H), 3.76 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.51 (t, J3b,3a = J3b,2 = 12.9 Hz, 
1H, C3-H-3b), 7.66-8.61 (9H, Ar-H). 
2.2.1.6. 2,3-Dihydro-2-(2,4-dichlorophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine 
(27): FT-IR (KBr): 1592 (C=N), 1526 (C=C), 1382 ( C-N), 688 (C-S), 945 (C-Cl), 3020 (Ar 
C-H); 1H NMR (400 MHz, CDCl3): 5.43 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.99 
(dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.62 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, 
C3-H-3b), 7.90-8.96 (9H, Ar-H). 
 
2.2.1.7. 2,3-Dihydro-2-(4-hydroxyphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine 
(28): FT-IR (KBr): 1596 (C=N), 1518 (C=C), 1388 (C-N), 667 (C-S), 915 (C-Cl), 3452 
(Ar-OH), 3024 (Ar C-H); 1H NMR (400 MHz, CDCl3): 4.72 (s, 1H, Ar-OH), 5.23 (dd, J2,3a = 
5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.51 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.28 
(t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 7.20-8.19 (10H, Ar-H). 
2.2.1.8. 2,3-Dihydro-2-(4-methylphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (29): 
FT-IR (KBr): 1588 (C=N), 1516 (C=C), 1390 (C-N), 678 (C-S), 888 (C-Cl), 2935 (Alkyl 
C-H), 3022 (Ar C-H); 1H NMR (400 MHz, CDCl3): 2.38 (s, 3H, Ar-CH3), 4.95 (dd, J2,3a = 
5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.32 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.11 
(t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 7.10-8.09 (10H, Ar-H). 
2.2.1.9. 2,3-Dihydro-2-(4-methoxyphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine 
(30): FT-IR (KBr): 1586 (C=N), 1519 (C=C), 1395 (C-N), 666 (C-S), 912 (C-Cl), 1219 
(-O-CH3), 3045 (Ar C-H); 1H NMR (400 MHz, CDCl3): 3.88 (s, 3H, Ar-OCH3), 5.10 (dd, 
J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.53 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, 
C3-H-3a), 3.26 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 6.52-7.83 (10H, Ar-H).  
2.2.1.10. 
2,3-Dihydro-2-(3-methoxy-4-hydroxyphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine 
(31): FT-IR (KBr): 1600 (C=N), 1515 (C=C), 1398 (C-N), 665 (C-S), 896 (C-Cl), 1222 
(-O-CH3), 3420 (Ar-OH), 3045 (Ar C-H); 1H NMR (400 MHz, CDCl3): 3.80 (s, 3H, 
Ar-OCH3), 4.91 (s, 1H, Ar-OH), 4.99 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.32 (dd, 
J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.06 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 
6.69-8.10 (9H, Ar-H).  
2.2.1.11. 
2,3-Dihydro-2-(4-dimethylaminophenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine 
(32): FT-IR (KBr): 1651 (C=N), 1519 (C=C), 1391 (C-N), 671 (C-S), 910 (C-Cl), 1205 
(-N(CH3)2), 3048 (Ar C-H); 1H NMR (400 MHz, CDCl3): 3.18 (s, 6H,-N(CH3)2, 5.28 (dd, 
J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.60 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, 
C3-H-3a), 3.41 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 6.65-8.07 (10H, Ar-H). 
2.2.1.12. 
2,3-Dihydro-2-(3,4-dimethoxyphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (33): 
FT-IR (KBr): 1615 (C=N), 1512 (C=C), 1329 (C-N), 682 (C-S), 1229 (-O-CH3), 3095 (Ar 
C-H).; 1H NMR (400 MHz, CDCl3): 3.83 (s, 3H, Ar-OCH3), 3.88 (s, 3H, Ar-OCH3), 5.01 
 
(dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.31 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, 
C3-H-3a), 3.11 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 6.85-8.06 (9H, Ar-H). 
2.2.1.13. 
2,3-Dihydro-2-(3,4,5-trimethoxyphenyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (34): 
FT-IR (KBr): 1599 (C=N), 1508 (C=C), 1371 (C-N), 1226 (-O-CH3), 694 (C-S), 901 (C-Cl), 
3014 (Ar C-H); 1H NMR (400 MHz, CDCl3): 3.70 (s, 6H, 2x Ar-OCH3), 3.95 (s, 3H, 
Ar-OCH3), 5.05 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.29 (dd, J3a,3b = 14.4 Hz, J3a,2 = 
9.9 Hz, 1H, C3-H-3a), 3.10 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 6.78-8.12 (10H, Ar-H). 
2.2.1.14. 2,3-Dihydro-2-(pyridin-2-yl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (35): 
FT-IR (KBr): 1595 (C=N), 1517 (C=C), 1396 (C-N), 672 (C-S), 886 (C-Cl), 1136 (-O-CH3), 
3025 (Ar C-H); 1H NMR (400 MHz, CDCl3): 5.03 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, 
C2-H), 3.29 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.12 (t, J3b,3a = J3b,2 = 12.9 Hz, 
1H, C3-H-3b), 6.85-8.14 (10H, Ar-H). 
2.2.1.15. 2,3-Dihydro-2-(pyridin-3-yl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (36): 
FT-IR (KBr): 1602 (C=N), 1504 (C=C), 1387 (C-N), 676 (C-S), 865 (C-Cl), 3031 (Ar C-H); 
1H NMR (400 MHz, CDCl3): 5.51 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.77 (dd, J3a,3b 
= 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.56 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 
7.45-8.49 (10H, Ar-H). 
2.2.1.16. 2,3-Dihydro-2-(pyridin-4-yl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (37): 
FT-IR (KBr): 1610 (C=N), 1517 (C=C), 1391 (C-N), 692 (C-S), 859 (C-Cl), 3171 (Ar C-H); 
1H NMR (400 MHz, CDCl3): 5.11 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.49 (dd, J3a,3b 
= 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.16 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 
7.18-8.28 (10H, Ar-H). 
2.2.1.17. 2,3-Dihydro-2-(4-thienyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (38): 
FT-IR (KBr): 1595 (C=N), 1525 (C=C), 1395 (C-N), 671 (C-S), 891 (C-Cl), 3012 (Ar C-H); 
1H NMR (400 MHz, CDCl3): 5.29 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.72 (dd, J3a,3b 
= 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.49 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 
7.10-8.12 (9H, Ar-H). 
2.2.1.18. 2,3-Dihydro-2-(2-furfuryl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (39): 
FT-IR (KBr): 1583 (C=N), 1511 (C=C), 1385 (C-N), 699 (C-S), 875 (C-Cl), 3129 (Ar C-H); 
1H NMR (400 MHz, CDCl3): 5.58 (dd, J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.55 (dd, J3a,3b 
 
= 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.34 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b), 
6.95-8.11 (9H, Ar-H). 
2.2.1.19. 2,3-Dihydro-2-(2-pyrrolyl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (40): 
FT-IR (KBr): 1592 (C=N), 1527 (C=C), 1399 (C-N), 682 (C-S), 917 (C-Cl), 3321 (N-H), 
3011 (Ar C-H); 1H NMR (400 MHz, CDCl3): 10.09 (s, 1H, -NH), 5.25 (dd, J2,3a = 5.1 Hz, J2,3b 
= 12 Hz, 1H, C2-H), 3.56 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.42 (t, J3b,3a = 
J3b,2 = 12.9 Hz, 1H, C3-H-3b), 6.87-8.15 (9H, Ar-H). 
2.2.1.20. 2,3-Dihydro-2-(pyrazol-5-yl)-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (41): 
FT-IR (KBr): 1588 (C=N), 1522 (C=C), 1387 (C-N), 669 (C-S), 911 (C-Cl), 3326 (N-H), 
3051 (Ar C-H); 1H NMR (400 MHz, CDCl3): 10.25 (s, 1H, N-H), 5.51 (dd, J2,3a = 5.1 Hz, J2,3b 
= 12 Hz, 1H, C2-H), 3.54 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, C3-H-3a), 3.21 (t, J3b,3a = 
J3b,2 = 12.9 Hz, 1H, C3-H-3b), 7.28-8.31 (8H, Ar-H).  
2.3. Antimicrobial activity 
The antimicrobial (antibacterial and antifungal) activities of the novel chloropyrazine 
clubbed benzothiazepines (22-41) was evaluated against selected bacterial and fungal strains 
using standard experimental procedures as described in the literature (Vegesna et al., 2017). 
The standard strains were procured from the American Type Culture Collection (ATCC) 
and Gene Bank, Institute of Microbial Technology, Chandigarh, India. The bacterial strains 
selected for the study were Bacillus subtilis (ATCC-60511), Staphylococcus aureus 
(ATCC-11632), Escherichia coli (ATCC-10536), Pseudomonas aeruginosa (ATCC-10145) 
whereas the fungal strains include Aspergillus niger (ATCC-6275) and Candida tropicalis 
(ATCC-1369) respectively. Ciprofloxacin was used as positive control for antibacterial 
studies and fluconazole for antifungal activity. Antibacterial activity was performed using 
nutrient agar medium whereas Potato Dextrose-Agar medium was used for antifungal 
testing. 2.048 mg of each test compound was taken in vials separately. Then 2 mL of 
methanol was added. Thus, a solution with a concentration of 1.024 mg/mL was obtained. 
All the experiments were carried out in triplicate and the results are presented as the mean of 
three independent experiments. The microbial strains were grown at 37 0C in their respective 
nutrient medium and diluted in sterile nutrient broth medium to get a suspension containing 
107 cells/mL and this suspension was used as the inoculum. All the test tubes were incubated 
 
for 18 h at 37 0C. A similar experiment with inoculum, medium and methanol without 
compound was furthermore performed to confirm that there is no inhibitory effect of 
methanol used for the dilutions. The test tube number in which the first sign of the growth of 
the organism observed was noted using a spectrophotometer. The MIC was determined for 
all the compounds by taking that concentration used in the test tube number just before the 
test tube number where the first sign of growth observed (Kasetti et al., 2020).  
2.4. Antitubercular activity 
Chalcone precursors (1-21) and conjugated 1,5-benzothiazepine derivatives (22-41) were 
evaluated for antitubercular activity using the same procedure which we described in our 
previous paper [Kishore et al., 2017, Lokesh et al., 2019, Palleapati et al., 2019] on 
Mycobacterium tuberculosis H37Rv strain (procured from National Institute of Tuberculosis, 
Chennai, India) using pyrazinamide (Sigma-Aldrich, USA) as reference drug. Broth dilution 
assay was employed to determine the minimum inhibitory concentration (MIC) of each 
compound. All the test compounds were dissolved separately in dimethyl sulfoxide (DMSO, 
(Merck Life Sciences Private Limited, Mumbai, India) and then diluted twice at the required 
concentration. A frozen culture in Middle brook 7H9 broth added with 10% 
albumin-dextrose-catalase and 0.2% glycerol (Himedia, Mumbai, India) was melted and 
diluted in broth to 105 cfu mL-1 (colony forming unit/mL) dilutions. The final concentration 
of DMSO in the assay medium was 1.3%. Then, each U-tube was inoculated with 0.05 mL of 
standardized culture and incubated at 37°C for 21 days. The growth in the U-tubes was 
compared with visibility in opposition to a negative control (without drug and inoculum), 
positive control (without drug), and with standard pyrazinamide. The MIC values obtained in 
µg/mL were converted into µM for the standard drug pyrazinamide and the target 
compounds (2-41) in order allow comparison in molecular level. 
2.5. Cytotoxic activities 
DU-145 (prostate cancer) and normal liver (L02) cell lines were obtained from National 
Centre for Cell Science (NCCS), Pune, India. DMEM (Dulbeccos Modified Eagels 
Medium), MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], Trypsin, 
EDTA were purchased from Sigma chemicals (St.Louis,MO). Fetal bovine serum (FBS) was 
purchased from Arrow Labs, 96 well flat bottom tissue culture plates were purchased from 
Tarson. The in vitro cytotoxic activity was performed for both chalcones (2-21) and 
benzothiazepines (22-41) on prostate cancer cell lines (DU-145) by Mosmann’s MTT assay 
(Mosmann, 1983) and their IC50 values were determined. The cytotoxic activity of the target 
 
compounds was compared with the standard drug methotrexate (Mtx). In principle, the assay 
is based on the reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) to formazan (blue-purple colored) product, due to the action of mitochondrial 
reductase enzyme inside the living cells. DU-145 cells were cultured in Dulbecco's Modified 
Eagle Medium (DMEM) at 37°C and humidified at 5% CO2. The test compounds (2-41) 
were dissolved in 0.1% DMSO to make their stock solutions. From these stock solutions, 
different dilutions of the compounds were made with sterile water to attain the required final 
concentrations. Briefly, the cells were placed on 96-well plates at 100 µL total volume with a 
density of 1 × 104 cells per well and were allowed to adhere for 24 h. Later, the medium was 
replaced with fresh media containing different dilutions of the test compounds and allowed to 
incubate for another 48 h at 37°C in DMEM with 10% fetal bovine serum (FBS) medium. 
Afterwards, the medium was replaced with 90 μL of fresh DMEM without FBS. The wells 
were treated with 10 μL of MTT reagent (5 mg/mL of stock solution in DMEM without FBS) 
and incubated at 37°C for 3-4 h. The formed blue crystals of formazan were dissolved in 200 
μL of DMSO, and the optical density was determined at 570 nm using micro plate reader. 
Assay was carried out in triplicate for three independent experiments. The results had good 
reproducibility between replicate wells with standard errors below 10%. The cytotoxic 
activity results measured as IC50 values in µg/mL were converted into µM. All the 
compounds were also evaluated for their cytotoxicity on normal human liver cell lines (L02) 
to determine their toxicity by using the identical protocol as described above.   
3. Results and discussion 
3.1. Chemistry 
Choloropyrazine based chalcones (2-21) and conjugated 1,5-benzothiazepines (22-41) 
described here were synthesized following the synthetic routes outlined in Scheme 1. To 
prepare chalcones 2-21, 2-acetyl-5-chloropyrazine was treated with substituted aromatic and 
heteroaromatic aldehydes in ethanol under basic conditions to obtain yields between 
55%-97% (Vegesna et al., 2017). Intermediates 2-21 were refluxed with 2-aminothiophenol 
to obtain target benzothiazepines 22-41 with yields between 58%-95% (Table 1). The 
compound 22 was analyzed for molecular formula C19H14ClN3S, m.p. 166-168°C, well 
supported by a M+ peak at m/z 351.85 and also a satellite peak at m/z 353.85 with 3:1 
intensity in its electron spray ionization mass spectrum. The FT-IR spectrum (cm-1) of the 
compound 22 showed the characteristic bands at 1584 (C=N), 1510 (C=C), 1395 (C-N), 663 
(C-S), 844 (C-Cl), and 3032 (Ar C-H). The 1H NMR spectrum of compound 22 showed three 
 
characteristic peaks of C2-H and C3-CH2 protons of 1,5-benzothiazepine ring at 5.11 (dd, 
J2,3a = 5.1 Hz, J2,3b = 12 Hz, 1H, C2-H), 3.52 (dd, J3a,3b = 14.4 Hz, J3a,2 = 9.9 Hz, 1H, 
C3-H-3a), and 3.21 (t, J3b,3a = J3b,2 = 12.9 Hz, 1H, C3-H-3b). The spectrum also accounted for 
the other twelve aromatic protons in between δ 7.19-8.22. The 13C NMR spectrum of 
compound 22 accounted for all the carbons whose resonance appeared at the following δ 
values: 50.15 (C-2), 40.24 (C-3), 164.66 (C-4), 122.54, 126.44, 127.51, 127.81, 128.80, 
133.31, 141.72, 144.46, 146.73, 150.32 and 151.45 (Ar-C’s). The values are consistent with 
the proposed structure for the compound. Based on the above spectral data and elemental 
analysis, the structure of compound 22 was confirmed as 
2,3-dihydro-2-phenyl-4-(5-chloropyrazin-2-yl)-1,5-benzothiazepine (Fig. 4). Similarly, 
other 19 compounds exhibited their characteristic spectral features in their FT-IR and 1H 
NMR spectra. The general structures and physicochemical properties of compounds 22-41 
are shown in Table 1. 
 
Table 1. Chemical structures and physicochemical properties of compounds 22-41. 
 
 
Entry Ar % Yield m.p. oC 
22 phenyl 90 166-168 
23 4-chlorophenyl 95 155-157 
24 4-fluorophenyl 92 171-173 
25 4-nitrophenyl 83 185-187 
26 2,4-difluorophenyl 79 121-123 
27 2,4-dichlorophenyl 88 133-135 
28 4-hydroxyphenyl 63 196-198 
29 4-methylphenyl 79 148-150 
30 4-methoxyphenyl 66 205-207 
31 3-methoxy-4-hydroxyphenyl 73 252-254 
32 4-dimethylaminophenyl 91 175-177 
33 3,4-dimethoxyphenyl 81 166-168 
34 3,4,5-trimethoxyphenyl 75 210-212 
35 2-pyridinyl 65 211-213 
36 3-pyridinyl 58 118-120 
37 4-pyridinyl 66 131-133 
38 2-thienyl 69 150-152 
39 2-furfuryl 80 142-144 
40 2-pyrrolyl 75 175-177 
41 5-pyrazolyl 82 232-236 
 
 
3.2. Antimicrobial activity 
All the compounds synthesized through this study were evaluated for their antimicrobial, 
antitubercular, and cytotoxic activities employing standard protocols. The compounds were 
classified into three different categories based on their structural features. Physicochemical 
properties modulated were based on the “R” group. Electron withdrawing or donating groups 
on phenyl ring (Tables 2-5) were either substituted at para position (3-5, 8-10 & 12; 23-25, 
28-30, and 32), ortho and para positions (6, 7, 26 & 27), or meta & para positions (11, 13, 14, 
31, 33 and 34). Bioisosteric substitution of phenyl ring with pyridyl, thienyl, furfuryl, 
pyrrolyl, and pyrazolyl systems resulted in compounds 15-21 and 35-41 as chalcone and 
benzothiazepine derivatives.  
3.2.1. Antibacterial activity 
Compounds 22-41 were evaluated for their antibacterial activity (Table 2) against Bacillus 
subtilis, Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa using 
ciprofloxacin as standard.  
Table 2. Antibacterial activity of benzothiazepines 22-41 (expressed as MIC in µM). 
 
 
Entry Ar B. subtilis 
 
S. aureus  E. coli 
 
P. aeruginosa 
22 phenyl >200 >200 >200 >200 
23 4-chlorophenyl 82.83 82.83 82.83 82.83 
24 4-fluorophenyl 86.52 86.52 86.52 86.52 
25 4-nitrophenyl 80.63 80.63 80.63 80.63 
26 2,4-difluorophenyl 41.25 41.25 41.25 41.25 
27 2,4-dichlorophenyl 38.02 38.02 38.02 38.02 
28 4-hydroxyphenyl >200 >200 >200 >200 
29 4-methylphenyl >200 174.92 >200 >200 
30 4-methoxyphenyl >200 >200 >200 >200 
31 3-methoxy-4-hydroxyph
enyl 
>200 >200 >200 >200 
32 4-dimethylaminophenyl 162.05 >200 >200 >200 
33 3,4-dimethoxyphenyl >200 >200 >200 >200 
34 3,4,5-trimethoxyphenyl 144.81 144.81 72.40 144.81 
35 2-pyridinyl >200 >200 >200 >200 
36 3-pyridinyl 181.38 >200 181.38 >200 
37 4-pyridinyl 181.38 181.38 181.38 181.38 
38 2-thienyl 178.83 >200 >200 178.83 
39 2-furfuryl >200 >200 >200 >200 
40 2-pyrrolyl >200 >200 >200 >200 
 
41 5-pyrazolyl >200 >200 >200 >200 
Ciprofloxacin 145.71 145.71 72.85 72.85 
 
The benzothiazepine series (22-41) (Table 2) overall antibacterial activity ranged from 
38->200 µM. For compounds 22-25, 28-30, and 32, the para position was substituted with 
either H (22), Cl (23), F (24), NO2 (25), OH (28), CH3 (29), OCH3 (30), and N(CH3)2 (32). 
Compound 22 with H substituent showed inactivity with MICs >200 µM against four 
bacterial species. Replacing H substituent (22) with electron withdrawing substituents 
chlorine (Cl) (23) fluorine (F) (24), or nitro (NO2) (25) resulted in MICs between 80-86 µM 
suggesting an improvement in the activity against four bacterial species over compound 22. 
Changing the para position of electron withdrawing to electron donating groups OH (28), 
CH3 (29), OCH3 (30), and N(CH3)2 (32), a trend similar to chalcones 8-10 and 12 (Vegnesa et 
al., 2017) was observed causing a significant loss in potency with MICs between 162->200 
µM indicating that electron withdrawing groups are favored over donating groups at the para 
position of the phenyl ring. 
Based on our data obtained from compounds 23-25, 28-30, and 32, we decided to synthesize 
few compounds having electron withdrawing and electron donating groups at ortho/para and 
meta/positions. As seen in compounds 26 and 27, they showed 2-fold improvement in the 
antibacterial activity (38.02-41.25 µM) over the compounds 23-25 with electron 
withdrawing groups (23-25; 80.63-86.52 µM), the most active being compound 27 (MIC 
38.02 µM). However, in case of disubstituted chalcones with electron donating groups 31 
and 33, it resulted in MICs between >200 µM, suggesting loss of activity similar to 
compounds 28-30.  
Among the bioisosteres (35-41), there was no improvement in the activity in comparison to 
the standard ciprofloxacin. The MICs varied between 178- >200 µM. The most potent among 
all benzothiazepines was compound 27 (MIC 38.02 µM) having two- to four-fold 
improvement in activity over ciprofloxacin against four bacterial species. Overall, chalcones 
(Vegnesa et al., 2017) fared better over benzothiazepine derivatives. Comparing between the 
two series, it can be inferred that in chalcone and benzothiazepine series, physicochemical 
property was modulated by electron withdrawing groups in ortho/para positions thereby 
improving the antibacterial activity.  
3.2.2. Antifungal activity 
The antifungal activity (Table 3) of benzothiazepine series (22-41) ranged from 19->200 
µM. Compound 22 with H substituent showed the lowest antibacterial activity with MIC of 
181 µM against two fungal species in comparison to compounds 23-34. Replacing H 
substituent (22) with electron withdrawing substituents chlorine (Cl) (23), fluorine (F) (24), 
 
or nitro (NO2) (25) resulted in MICs between 40-43 µM suggesting 4.2-4.5-fold 
improvement in the activity against two fungal species, respectively, over compound 22. 
Changing the para position from electron withdrawing to electron donating groups OH (28), 
CH3 (29), OCH3 (30), and N(CH3)2 (32) resulted in a trend similar to chalcones 8-10 and 12 
causing a significant drop in the activity with MICs between 162-174 µM against A. niger 
and 173.98- >200 µM against C. tropicalis. 
 
 
Table 3. Antifungal activities of benzothiazepines (22-41) (expressed as MIC in µM). 
 
Entry Ar A. niger 
 
C. tropicalis 
22 phenyl 181.91 181.91 
23 4-chlorophenyl 41.41 41.41 
24 4-fluorophenyl 43.26 43.26 
25 4-nitrophenyl 40.31 40.31 
26 2,4-difluorophenyl 20.62 20.62 
27 2,4-dichlorophenyl 19.01 19.01 
28 4-hydroxyphenyl 173.98 173.98 
29 4-methylphenyl 174.92 174.92 
30 4-methoxyphenyl 167.59 >200 
31 3-methoxy-4-hydroxyphenyl >200 >200 
32 4-dimethylaminophenyl 162.05 >200 
33 3,4-dimethoxyphenyl 38.84 155.37 
34 3,4,5-trimethoxyphenyl 36.20 36.20 
35 2-pyridinyl 90.69 45.34 
36 3-pyridinyl 45.34 45.34 
37 4-pyridinyl >200 90.69 
38 2-thienyl 44.70 44.70 
39 2-furfuryl 93.61 187.23 
40 2-pyrrolyl >200 187.77 
41 5-pyrazolyl 187.23 187.23 
Fluconazole 84.14 63.10 
 
Electron withdrawing groups at ortho/para positions as seen in compounds 26 and 27 showed 
two-fold improvement in the antibacterial activity (19.01-20.62 µM) over compounds 23-25 
with electron withdrawing groups (23-24; 40.31-43.26 µM). Compounds 26 & 27 (MICs 
20.62 & 19.01 µM) had similar antifungal activity. However, in case of electron donating 
groups 31 (meta/para) and 33 (meta/para), it resulted in MICs between 38.84- >200 µM with 
 
compound 33 (MIC 38.84 µM) having better activity against A. niger over compound 30 
(MIC 167.59 µM vs A. niger).  
The MICs of bioisosteres 35-41 varied between 44-751 µM. Among the six-membered 
pyridine ring containing bioisosteres (35-37), compound 36 showed the best activity of 45.34 
µM. Although among five-membered heterocycles, the 2-thienyl containing benzothiazepine 
38 showed the best activity of 44.70 µM; it was comparatively less than standard 
fluconazole. The most potent among all benzothiazepines identified was compound 27 (MIC 
19.01 µM) having three- to four-fold improvement in activity over fluconazole. Overall, 
benzothiazepines were found to have comparable activity with chalcones (Vegesna et al., 
2017). 
 
3.3. Antitubercular activity 
Chalcone (2) with H substituent showed the modest antifungal activity with MIC 130.78 
µM against M. tuberculosis (Table 4). Replacing H substituent (2) with electron 
withdrawing substituents chlorine (Cl) (3) and fluorine (F) (4) resulted in MICs between 
57-60 µM suggesting nine-fold enhancement in the activity against two fungal species. 
Substitution of halogens with a nitro group 5 resulted in four-fold decrease in activity over 3 
and 4. It was observed that compounds 8, 9, 10, and 12 having electron donating groups 
caused a significant drop in the activity (MICs 116-491 µM).  
    Having electron withdrawing groups at ortho and para position of phenyl ring 
resulted in further improvement in antitubercular activity by two-fold (7 vs 3, MICs 25.51 vs 
57.32 µM; 6 vs 4, MICs 28.50 vs 60.91 µM). Substituting meta and para position with 
electron donating groups (compounds 11 and 13) showed modest activity (MICs 52-110 
µM), with compound 13 having better activity over compound 11. Interestingly, substituting 
the para and the two meta positions with methoxy substituent 14 improved the activity to 
23.89 µM. Compound 14 was identified as the most potent of all the synthesized chalcones 
having 17-fold improved activity over pyrazinamide (MIC 412.76 µM). The next in potency 
among the chalcone series was compound 7 having MIC of 25.51 µM. Bioisoster-based 










Table 4. Antitubercular activities of chalcones (2-21) and benzothiazepines (22-41) (expressed 
as MIC in µM). 
 










2 phenyl 130.78 22 181.89 
3 4-chlorophenyl 57.32 23 82.83 
4 4-fluorophenyl 60.91 24 43.26 
5 4-nitrophenyl 220.93 25 322.54 
6 2,4-difluorophenyl 28.50 26 41.25 
7 2,4-dichlorophenyl 25.51 27 38.02 
8 4-hydroxyphenyl 491.02 28 >500 
9 4-methylphenyl 123.69 29 174.92 
10 4-methoxyphenyl 116.49 30 167.59 
11 3-methoxy-4-hydroxyphenyl 110.07 31 160.85 
12 4-dimethylaminophenyl 444.83 32 324.11 
13 3,4-dimethoxyphenyl 52.50 33 38.84 
14 3,4,5-trimethoxyphenyl 23.89 34 18.10 
15 2-pyridinyl >500 35 >500 
16 3-pyridinyl >500 36 >500 
17 4-pyridinyl >500 37 >500 
18 2-thienyl >500 38 >500 
19 2-furfuryl >500 39 >500 
20 2-pyrrolyl >500 40 >500 
21 5-pyrazolyl >500 41 >500 
Pyrazinamide  412.76 
 
The benzothiazepine series (22-41) fared slightly better than the chalcones (Table 4). The 
overall antitubercular activity ranged from 18-1497 µM. Compound 22 with H substituent 
showed the modest antibacterial activity with MIC of 181.89 µM. Substituting H substituent 
(22) with electron withdrawing substituents chlorine (Cl) (23) and fluorine (F) (24) resulted 
in MICs between 43-82 µM, suggesting two- to + improvement in the activity against M. 
tuberculosis over compound 22. However, inserting a 4-nitro (25) substituent surprisingly 
proved to be deleterious for the activity in comparison to compounds 23 and 24. This trend 
was found to be similar to chalcones 3, 4 in comparison to 5. Changing the para position from 
electron withdrawing to electron donating groups OH (28), CH3 (29), OCH3 (30), and 
N(CH3)2 (32) resulted in attenuation in activity with MICs between 167- >500 µM, which 
highlights the importance of electron withdrawing group on the potency. 
 
Electron withdrawing groups at ortho/para positions as seen in compounds 26 and 27 
showed either similar or two-fold improvement in the antitubercular activity (38.02-41.25 
µM) over the compounds 23-25 with electron withdrawing groups (23-24; 43.26-82.83 µM), 
the most active being compound 27 (MIC 38.02 µM). Additionally, in case of electron 
donating groups 31 (meta/para), 33 (meta/para), it resulted in MICs between 38.84-160.85 
µM, with compound 33 having 4.3-fold better activity over compound 30 (MIC 167.59 µM). 
Interestingly, compound 34 having three methoxy groups at positions 3, 4, and 5 on the 
phenyl ring resulted in two-fold improvement in activity over compound 33, a trend found 
similar in chalcones (14 vs 13).  
Introducing bioisosteric replacement for phenyl ring did not show any improvement in MICs 
as compounds 35-41 displayed inactivity with MICs >500 µM. The activity trend of 
benzothiazepines were similar to chalcones (27 vs 7 and 34 vs 14). The most potent 
compound identified was 34 (MIC 18.01 µM) having 23-fold improvement in activity over 
pyrazinamide. Overall, benzothiazepines were found to have antitubercular activity 
comparable with chalcones (34 vs 14; MICs 18.01 vs 23.89 µM). 
 
3.4. Cytotoxic activities 
All the 40 compounds were evaluated for their cytotoxic activity against prostate cancer 
cell line, DU-145, employing MTT assay (Table 5). Among the chalcone series, compound 7 
was found to be the most potent with IC50 46.03 ± 1 µM, whereas in benzothiazepine series, 
compound 41 had 1.3-fold better activity over 7 with the IC50 of 35.10 ± 2 µM. The activity 
of these compounds was found to be 3-4–fold less than the standard, methotrexate (IC50 = 11 
± 1 µM). The compounds 4, 6, 26, and 35 were next in activity with IC50 values 124.27 ± 1, 
121.18 ± 2, 72.19 ± 2 and 51.01 ± 1 µM, respectively. All the other compounds exhibited 
modest to inactivity with MICs ranging from 99.82 ± 2 to > 200 µM. The structure activity 
relationship (SAR) features of chalcones and benzothiazepines indicated that electron 
withdrawing group (Cl) at ortho and para positions (7) and 5-pyrazolyl heterocyclic ring (41) 
played a key role in cytotoxic activity. The compounds were also tested against the human 
normal liver cells (L02) and were found to be less selective towards this cell type as the IC50 
is beyond the highest concentration tested. (Table 6). A summary of the antibacterial, 
antifungal, antitubercular, and cytotoxic activities of chalcones (2–21) and benzothiazepines 






Table 5. Cytotoxic activity results of chalcones (2-21) and benzothiazepines (22-41) (IC50 





























# Ar DU-145 # DU-145 
2 phenyl >200 22 122.21 ± 1 
3 4-chlorophenyl >200 23 119.08± 2 
4 4-fluorophenyl 124.27 ± 1 24 156.82± 2 
5 4-nitrophenyl >200 25 >200 
6 2,4-difluorophenyl 121.18± 2 26 72.19± 2 
7 2,4-dichlorophenyl 46.03 ± 1 27 99.82± 2 
8 4-hydroxyphenyl >200 28 >200 
9 4-methylphenyl >200 29 >200 
10 4-methoxyphenyl >200 30 >200 
11 3-methoxy-4-hydroxyphenyl >200 31 >200 
12 4-dimethylaminophenyl >200 32 121.54± 2 
13 3,4-dimethoxyphenyl >200 33 >200 
14 3,4,5-trimethoxyphenyl >200 34 158.39± 2 
15 2-pyridinyl >200 35 51.01 ± 1 
16 3-pyridinyl >200 36 >200 
17 4-pyridinyl >200 37 181.38 ± 2 
18 2-thienyl >200 38 >200 
19 2-furfuryl >200 39 >200 
20 2-pyrrolyl >200 40 >200 
21 5-pyrazolyl >200 41 35.10 ± 2 
Methotrexate 11 ± 1 
Data presented as mean ± SD (n=3). All the compounds and the standard dissolved in DMSO, diluted with culture medium containing 0.1% 
DMSO. The control cells were treated with culture medium containing 0.1% DMSO. 
 
 
Table 6. Cytotoxic activity (IC50 in µg/mL) of chalcones (2–21) and benzothiazepines 
(22–41). 
 
Entry Ar L02 # L02 
2 phenyl >50 22 >40 
3 4-chlorophenyl >50 23 >40 
4 4-fluorophenyl >50 24 >40 
5 4-nitrophenyl >50 25 >40 
6 2,4-difluorophenyl >50 26 >40 
7 2,4-dichlorophenyl >50 27 >40 
8 4-hydroxyphenyl >50 28 >40 
9 4-methylphenyl >50 29 >40 
10 4-methoxyphenyl >50 30 >40 
11 3-methoxy-4-hydroxyphenyl >50 31 >40 
12 4-dimethylaminophenyl >50 32 >40 
13 3,4-dimethoxyphenyl >50 33 >40 
14 3,4,5-trimethoxyphenyl >50 34 >40 
15 2-pyridinyl >50 35 >40 
16 3-pyridinyl >50 36 >40 
17 4-pyridinyl >50 37 >40 
18 2-thienyl >50 38 >40 
19 2-furfuryl >50 39 >40 
20 2-pyrrolyl >50 40 >40 












Data presented as mean ± SD (n=3). All the compounds and the standard dissolved in DMSO, diluted with culture medium containing 0.1% 
DMSO. The control cells were treated with culture medium containing 0.1% DMSO. 
 
 
Figure 4. Summary of the antibacterial, antifungal, antitubercular, and cytotoxic activities 
of chalcones (2–21) and benzothiazepines (22–41).  
4. Conclusions 
In our ongoing projects on the synthesis of compounds with potential antimicrobial, 
antitubercular, and cytotoxic activities, we have here reported 20 new compounds bearing 
benzothiazepine nucleus and evaluated our 20 previously reported chalcones for 
antitubercular and cytotoxic activities. Biological data indicated that benzodiazepines 
 
demonstrated excellent antifungal and antitubercular activities. It was observed that the 
electronic property (electron withdrawing and electron releasing) of the substituents on the 
phenyl ring was instrumental for the difference in the potency of the compounds. For 
instance, among benzothiazepines, electron withdrawing groups resulted in excellent 
antimicrobial and antifungal activity. Structure activity relationship studies of chalcones 
indicated that electronic properties did not play a key role for antitubercular activities as 
evident by compounds 7 and 14 whereas a similar phenomenon was observed for 
benzothiazepine 34. None of the compounds showed any improvement in cytotoxic activity 
over the standard drug methotrexate. All the compounds were found to be relatively less 
selective towards the human normal liver cell line LO2. Further studies are under progress to 
assess the computational binding characteristics of chalcones and benzodiazepines, which 
can give a fair understanding of newer analogs. 
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